key: cord-0942890-auf9dlqf
authors: Al-Dorzi, Hasan M; Kress, John; Arabi, Yaseen M.
title: High-flow nasal oxygen and non-invasive ventilation for COVID-19
date: 2022-01-10
journal: Crit Care Clin
DOI: 10.1016/j.ccc.2022.01.006
sha: b41874f86d602e9ada7131a334cbe1cf96a1e7c5
doc_id: 942890
cord_uid: auf9dlqf

High-flow nasal oxygen (HFNO) and non-invasive ventilation (NIV) via face-mask or helmet have been increasingly used in the management of acute hypoxemic respiratory failure (AHRF) due to COVID-19 with the premise of reducing the need for invasive mechanical ventilation and possibly mortality. However, their use carries the risk of delaying intubation and nosocomial infection transmission. To this date, most studies on the effectiveness of these modalities are observational and suggest that HFNO and NIV have a role in the management of AHRF due to COVID-19. A randomized controlled trial among patients with COVID-19 showed that helmet NIV versus HFNO led to a lower intubation rate but no difference in survival or the duration of respiratory support. The RECOVERY respiratory support trial demonstrated that CPAP, but not HFNO reduced a composite outcome of tracheal intubation or mortality within 30-days compared with conventional oxygen therapy. Additional trials are ongoing and are evaluating different aspects of noninvasive respiratory support in patients with AHRF due to COVID-19.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to > 240 million cases of Coronavirus Disease 2019 (COVID- 19) and approximately 4.9 million fatalities by August 10, 2021. [1] COVID-19 is a systemic disease, with a wide spectrum of disease severity ranging from asymptomatic to life-threatening.

The main reason for hospitalization and admission to ICU is the development of acute hypoxemic respiratory failure (AHRF), [2] that is frequently severe. [3, 4] The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) database suggests that 20% of patients with COVID-19 are admitted to an intensive care unit (ICU) or a high dependency unit at some point during their illness. [5] Respiratory support options for patients with AHRF in COVID-19 pneumonia include conventional oxygen therapy, oxygen by high-flow nasal oxygen (HFNO), and noninvasive positive pressure ventilation (NIV) in addition to invasive mechanical ventilation. [6] [7] [8] The ISARIC database showed that HFNO was used in 14%, NIV in 15% and invasive mechanical ventilation in 11% of hospitalized patients. [5] Early in the pandemic, invasive mechanical ventilation was the preferred modality for treating severe cases, partly due to the concerns over aerosolization associated with other forms of oxygen therapy, especially with reports of intrahospital transmission among healthcare workers (HCWs). [9] Early clinical practice guidelines on the use of NIV and HFNO in COVID-19 were cautious. For example, the WHO interim guidelines published in May 2020 stated that a trial of HFNO and NIV may be used in selected patients with COVID-19 and mild ARDS. [10] As high mortality was observed in intubated patients (Table 1) , NIV and HFNO were increasingly used, [11] which paved the way for conducting clinical studies.

In this review, we focus on the published evidence of the safety and effectiveness of HFNO and NIV for the management of patients with AHRF due to COVID-19.

acute hypoxemic respiratory failure HFNO achieves its main beneficial effects through the provision of high flow of gases. It uses humidification and heat to allow the delivery of up to 100% oxygen at J o u r n a l P r e -p r o o f high flow rates (usually 40-60 L/min) that can be tolerated by patients for extended time periods. The main mechanisms of action are: 1-washout of nasopharyngeal dead space, thus reducing the overall dead space, improving the elimination of carbon dioxide and enhancing oxygenation; 2-attenuation of the inspiratory resistance of the nasopharynx, and thus reducing the related work of breathing; 3improving conductance and pulmonary compliance by the adequately warmed and humidified gas compared to dry, cooler gas; 4-reducing the metabolic work associated with gas conditioning; and 5-the application of positive distending pressure for lung recruitment. [12] HFNO generates a very low positive end expiratory pressure (PEEP) effect (3 cmH2O on average), though it is higher with increasing flow. [13] The utilization of delivered oxygen is higher with HFNO compared with NIV at the same set fraction of inspired oxygen (FiO2), hence increasing the risk of depletion of hospital oxygen supply.

NIV is primarily a pressure-targeted modality delivered as continuous (CPAP) or biphasic positive airway pressure (mainly as pressure support ventilation [PSV]). It improves arterial oxygenation by increasing functional residual capacity, shifting the tidal volume to a more compliant part of the pressure-volume curve, thus reducing both the work of breathing and the tidal opening and closure of the airways. [14] The face-mask and helmet interfaces are commonly used to deliver NIV. The helmet has the advantage of less air leaks and better tolerability in many patients, thus facilitating prolonged NIV treatments at higher PEEP. [15] The main settings, strengths, and risks of HFNO, face-mask NIV and helmet NIV are presented in Figure 1 .

Both NIV and HFNO can avoid the complications associated with invasive mechanical ventilation, most importantly ventilator-induced lung injury, cardiovascular decompensation and infectious complications. [16, 17] However, the concerns associated with NIV and HFNO use in patients with COVID-19 include patient self-inflicted lung injury, delayed intubation in case of treatment failure and virus nosocomial transmission. [18] J o u r n a l P r e -p r o o f

In patients with AHRF, hypoxemia and dysregulated inspiratory effort may induce spontaneous vigorous inspiratory efforts. The resulting high transpulmonary pressures along with altered respiratory mechanics and inhomogeneous lung inflation may induce further injury to the lung, which is described as patient selfinflicted lung injury. [15, 19, 20] HFNO and NIV may mitigate partially, but not fully, these pathophysiologic abnormalities. Patient self-inflicted lung injury is difficult to quantify or even detect and related studies that compare non-invasive oxygen therapy versus invasive mechanical ventilation are lacking. From a mechanistic point of view, NIV has theoretical advantages over HFNO for the management of patients with COVID-19 and AHRF. [21] The ability of NIV to deliver higher PEEP compared to HFNO may render spontaneous breathing less injurious. [22] 

One of the concerns with the use of HFNO or NIV is delayed intubation that may worsen outcomes. Related studies showed mixed results and are based mainly on observational data. In a propensity score-matched retrospective study of 175 patients with non-COVID- 19 

The viral dispersion with HFNO has been evaluated in simulation and clinical studies. A study measured smoke dispersion distance from a manikin model with J o u r n a l P r e -p r o o f HFNO at 60 L/min, and demonstrated that smoke dispersion distance was limited suggesting that dispersion was similar to the one observed with simple oxygen mask. [25, 26] Wearing a surgical mask on top of HFNO further reduces the aerosol transmission during coughing or sneezing. [27] An experiment in healthy volunteers showed that cough-generated droplets spread to a mean (standard deviation) distance of 2.48±1.03 m at baseline and 2.91±1.09 m with HFNO (maximum cough distance of 4.50 m). [28] Face-mask NIV delivered through devices with single-limb circuits has been associated with more viral dispersion than HFNO.[29, 30] Using a human-patient simulator on face-mask NIV, the exhaled air dispersion distance was shown to increase with higher inspiratory positive airway pressures and was within a 

The prolonged use of NIV and to less extent HFNO in patients with COVID-19 is associated with the risk of pressure injury, especially in the nasal area, and with an increased risk of pulmonary barotrauma.

[39] Helmet-NIV eliminates the risk of pressure injury associated with face-mask interfaces, but may uncommonly be associated with other pressure injuries around the neck seal and underneath the axillary straps.

A meta-analysis of 9 randomized controlled trials (RCTs) (n=2093 patients) found no difference in mortality in patients with AHRF treated with HFNO (relative risk, 0.94; 95% confidence interval [CI] 0.67-1.31, moderate certainty) compared to conventional oxygen therapy, but a decreased risk of intubation (relative risk, 0.85; 95% CI, 0.74-0.99).

[40] A meta-analysis of 8 RCTs comparing high-flow nasal cannula to other noninvasive methods of oxygen delivery after extubation in critically ill adults found that HFNO compared with conventional oxygen therapy decreased reintubation (relative risk, 0.46; 95% CI, 0.30-0.70; moderate certainty) and postextubation respiratory failure, but had no effect on mortality (relative risk, 0.93; 95% CI, 0.57-1.52; moderate certainty), or ICU length of stay (mean difference, 0.05 days J o u r n a l P r e -p r o o f fewer; 95% CI 0.83 days fewer to 0.73 days more; high certainty). [41] In this population, HFNO compared with NIV, had no effect on reintubation, mortality, or post-extubation respiratory failure. [41] A systematic review and network meta-analysis that included 25 RCTs and 3804 patients with AHRF due to causes other than COVID-19 found lower mortality risk associated with face-mask NIV (risk ratio, 0.83; credible interval, 0.68-0.99) and helmet NIV (risk ratio, 0.40; credible interval, 0.24-0.63) compared with conventional oxygen therapy. [42] The benefit of helmet NIV but not face-mask NIV was maintained after excluding patients with COPD exacerbation or cardiogenic pulmonary edema. [42] Face-mask NIV, helmet NIV and HFNO were associated with lower risk of endotracheal intubation. [42] 

A simulation model projected that a scenario in which HFNO is available would result in 10,000-40,000 fewer deaths in the United States compared to a scenario in which HFNO was unavailable and fewer days without available ventilators. [43] A retrospective study evaluated 379 consecutive patients with COVID-19 admitted to the four ICUs for AHRF in Paris, France, between February 21 and April 24, 2020.

The 146 (39%) patients who received HFNO within the first 24 h after ICU admission were compared with the 233 patients who did not. Propensity-score adjusted analysis showed that HFNO was associated with fewer patients requiring invasive mechanical ventilation by Day 28 (55% versus 72%; p< 0.0001) with similar 28-day mortality (21% in the HFNO group versus 22% in the other group). [44] Other studies on the outcomes associated with HFNO in COVID-19 patients are summarized in Table 1 .

There are multiple observational studies that evaluated NIV in the management of COVID-19 in different settings that vary between ICU and wards, mostly due to unavailability of ICU beds ( Although the multivariable regression attempted to address bias inherent in this nonrandomized study, it is not clear whether the higher mortality in this study reflects severity of illness in those intubated or a true cause and effect. [45] In patients with J o u r n a l P r e -p r o o f confirmed COVID-19 treated in respiratory units outside the ICU with either HFNO (n=163, 24.3%) or CPAP/NIV (n=507, 75.7%), the intubation rate was similar in the two groups, but the mortality was lower in the HFNO group. [36] In an interim analysis of the international, multicenter HOPE COVID-19 cohort (1933 patients), 390 (20%) patients were treated with NIV, 44.4% of whom had the composite outcome of death or need for intubation. [46] Other studies on the outcomes associated with NIV in COVID-19 patients are summarized in Table 1 .

A recent RCT conducted in patients with COVID-19 admitted to 4 Italian ICUs with moderate-severe AHRF found that helmet NIV did not result in significantly fewer days of respiratory support at 28 days (primary outcome) as compared with HFNO alone (mean difference 2 days, 95% CI, -2 to 6, p=0.26). [47] However, the helmet NIV group had lower intubation rate (30% versus 51%; p=0.03) and more days free of invasive mechanical ventilation within 28 days (median of 28 versus 25 days; p=0.04). [47] The hospital mortality was 24% in the helmet NIV group and 25% in the high-flow nasal oxygen group. [47] In the RECOVERY-Respiratory Support multicenter RCT, 1272 hospitalized patients with acute respiratory failure due to COVID-19 were randomized to CPAP (n=380, 29.9%), HFNO (n=417, 32.8%) or conventional oxygen therapy (n=475, 37.3%). [48] The composite outcome (tracheal intubation or mortality within 30-days) was lower in the CPAP group compared with conventional oxygen therapy (CPAP group 36.3%, conventional oxygen therapy 44.4%, unadjusted odds ratio 0.72, 95% CI 0.53 to 0.96, p=0.03), but similar in the HFNO and conventional oxygen therapy groups (HFNO 44.4% vs. conventional oxygen therapy 45.1%; unadjusted odds ratio 0.97; 95% CI 0.73 to 1.29, p = 0.85). [48] . There are no data from RCTs that compares CPAP to pressure support mode.

Awake prone positioning can easily be performed in patients receiving HFNO. In a pilot study of 9 patients with COVID-19 and AHRF requiring HFNO for > 2 days, prone positioning led to increase in blood oxygen saturation (SaO2) from 90%±2% to J o u r n a l P r e -p r o o f 96%±3% (p<0.001) and in blood oxygen partial pressure(PaO2) from 69±10 to 108±14 mmHg (p<0.001). [49] Awake prone positioning has also been utilized in patients with COVID-19 while receiving NIV, but data are limited. Small observational studies have shown that NIV in the prone position is feasible and is probably safe, even outside the ICU. [50, 51] In a priori collaborative meta-trial of six randomized controlled trials, adults who required respiratory support with high-flow nasal cannula for AHRF due to COVID-19 (n=1126) were randomly assigned to awake prone positioning or standard care. The primary composite outcome was treatment failure (intubation or death within 28 days) was lower with awake prone positioning compared to standard care (40% versus 46%, relative risk 0·86 [95% CI 0·75−0·98]). [52] Monitoring of patients during high-flow nasal oxygen and noninvasive ventilation The success of the new modalities of non-invasive oxygen therapy starts with ensuring availability, having the needed infrastructure and resources, and establishing programs that train HCWs as well as creating protocols, policies and procedures on their use (Figure 1) . Close monitoring and short-interval assessments for worsening of respiratory failure are critical for patients receiving non-invasive oxygen therapy (Figure 1 ). [53] Monitoring during HFNO and NIV should encompass monitoring the inspiratory effort, respiratory rate, tidal volume, FiO2 and oxygenation parameters (SaO2/FiO2 or PaO2/FiO2 ratio), as these variables may indicate HFNO or NIV failure and the need for intubation. [15] A small retrospective study evaluated 17 patients with ARDS secondary to COVID-19 who were managed with HFNO. [54] The HFNO failure rate, defined by the need of NIV or intubation as rescue therapy, was 0% (0/6) in patients with PaO2/FiO2 > 200 mmHg versus 63% (7/11) There is evidence that ROX index may also predict the success of NIV to avoid delay in intubation. [58] Another index, the HACOR scale, which incorporates heart rate, acidosis, consciousness, oxygenation, and respiratory rate, may also predict NIV failure. [59] 

Multiple RCTs on noninvasive oxygen therapy in COVID-19 are ongoing ( Table   2) FiO2: fraction of inspired oxygen, NIV: noninvasive ventilation, PEEP: positive end expiratory pressure, PF ratio: the ratio of arterial oxygen partial pressure to fractional inspired oxygen, PSV:

pressure support

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Respiratory mechanics and gas exchange in COVID-19-associated respiratory failure

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

ISARIC clinical data report

Clinical Characteristics of Coronavirus Disease 2019 in China

Respiratory support for patients with COVID-19 infection

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in

Clinical management of COVID-19: interim guidance

Observational study of changes in utilization and outcomes in non-invasive ventilation in COVID-19

Research in high flow therapy: mechanisms of action. Respiratory medicine

The effects of flow on airway pressure during nasal high-flow oxygen therapy

Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia

Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS

Static and dynamic contributors to ventilator-induced lung injury in clinical practice. Pressure, energy, and power. American journal of respiratory and critical care medicine

Right ventricular failure in acute lung injury and acute respiratory distress syndrome

Use of non-invasive ventilation for patients with COVID-19: a cause for concern?

Management of COVID-19 Respiratory Distress

Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. American journal of respiratory and critical care medicine

Non-invasive ventilation in the treatment of early hypoxemic respiratory failure caused by COVID-19: considering nasal CPAP as the first choice

High positive end-expiratory pressure renders spontaneous effort noninjurious

Failure of high-flow nasal cannula therapy may delay intubation and increase mortality

High-flow nasal cannula in COVID-19: Outcomes of application and examination of the ROX index to predict success

Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks

Airflow and droplet spreading around oxygen masks: a simulation model for infection control research

Exhaled air dispersion during coughing with and without wearing a surgical or N95 mask

The impact of high-flow nasal cannula (HFNC) on coughing distance: implications on its use during the novel coronavirus disease outbreak

High-flow nasal cannula compared with conventional oxygen therapy or noninvasive ventilation immediately postextubation: a systematic review and meta-analysis

Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis

The impact of high-flow nasal cannula use on patient mortality and the availability of mechanical ventilators in COVID-19

High-flow nasal cannula in critically III patients with severe COVID-19

Non-invasive ventilation versus mechanical ventilation in hypoxemic patients with COVID-19

Noninvasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial

An adaptive randomized controlled trial of noninvasive respiratory strategies in acute respiratory failure patients with COVID-19

Prone positioning in high-flow nasal cannula for COVID-19 patients with severe hypoxemia: a pilot study

Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit

Investigators RC: Conscious prone positioning during non-invasive ventilation in COVID-19 patients: experience from a single centre

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. The Lancet Respiratory medicine

Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing

An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. American journal of respiratory and critical care medicine

High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. Multidisciplinary respiratory medicine

ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis

The ROX index can be a useful tool for the triage evaluation of COVID-19 patients with dyspnoea

Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients

Helmet Non-Invasive Ventilation for COVID-19 Patients (Helmet-COVID): study protocol for a multicentre randomised controlled trial

Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19

Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic

The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19. The American journal of emergency medicine 2021

Noninvasive Ventilatory Support of Patients with COVID-19 outside the Intensive Care Units (WARd-COVID)

High failure rate of noninvasive oxygenation strategies in critically ill subjects with acute hypoxemic respiratory failure due to COVID-19

Improved survival following ward-based non-invasive pressure support for severe hypoxia in a cohort of frail patients with COVID-19: retrospective analysis from a UK teaching hospital

Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study

Investigators R--I: Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study

Mortality of patients with severe COVID-19 in the intensive care unit: an observational study from a major COVID-19 receiving hospital

Bilevel and continuous positive airway pressure and factors linked to all-cause mortality in COVID-19 patients in an intermediate respiratory intensive care unit in Italy

Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain

Declining Intensive Care Unit Mortality of COVID-19: A Multi-Center Study

Role of Intermediate Care Unit Admission and Noninvasive Respiratory Support during the COVID-19 Pandemic: A Retrospective Cohort Study